M

Maat Pharma SA
PAR:MAAT

Watchlist Manager
Maat Pharma SA
PAR:MAAT
Watchlist
Price: 7.82 EUR 2.09% Market Closed
Market Cap: 108.6m EUR
Have any thoughts about
Maat Pharma SA?
Write Note

Gross Margin
Maat Pharma SA

67.9%
Current
76%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
67.9%
=
Gross Profit
1.7m
/
Revenue
2.6m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
FR
Maat Pharma SA
PAR:MAAT
106.6m EUR
68%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
320.1B USD
67%
US
Amgen Inc
NASDAQ:AMGN
147.4B USD
60%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD
86%
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD
78%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
135.4B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
34.3B EUR
89%
Country FR
Market Cap 106.6m EUR
Gross Margin
68%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 320.1B USD
Gross Margin
67%
Country US
Market Cap 147.4B USD
Gross Margin
60%
Country US
Market Cap 119.4B USD
Gross Margin
86%
Country US
Market Cap 113.8B USD
Gross Margin
78%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 135.4B AUD
Gross Margin
52%
Country US
Market Cap 82.6B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 34.3B EUR
Gross Margin
89%
No Stocks Found

Maat Pharma SA
Glance View

Market Cap
108.8m EUR
Industry
Biotechnology

Maat Pharma SA operates as a clinical-stage microbiome therapeutics company. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 43 full-time employees. The company went IPO on 2021-11-08. The firm specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.

MAAT Intrinsic Value
7.32 EUR
Overvaluation 6%
Intrinsic Value
Price
M

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
67.9%
=
Gross Profit
1.7m
/
Revenue
2.6m
What is the Gross Margin of Maat Pharma SA?

Based on Maat Pharma SA's most recent financial statements, the company has Gross Margin of 67.9%.